The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The initial consideration for the transaction is US$ 12 million
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Subscribe To Our Newsletter & Stay Updated
